Cellectis (NASDAQ:CLLS) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLSFree Report) in a report released on Thursday. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, JMP Securities reissued a market outperform rating and set a $6.00 target price on shares of Cellectis in a research report on Friday, May 31st.

Check Out Our Latest Report on CLLS

Cellectis Stock Performance

Cellectis stock opened at $2.67 on Thursday. The company has a market capitalization of $148.41 million, a P/E ratio of -2.07 and a beta of 3.09. The business has a 50 day moving average of $2.77 and a 200-day moving average of $2.84. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.63 and a quick ratio of 1.63. Cellectis has a 1 year low of $0.96 and a 1 year high of $3.77.

Cellectis (NASDAQ:CLLSGet Free Report) last released its earnings results on Monday, April 29th. The biotechnology company reported ($0.64) earnings per share for the quarter. The firm had revenue of $1.99 million for the quarter. Cellectis had a negative net margin of 529.81% and a negative return on equity of 67.41%. On average, equities research analysts predict that Cellectis will post -1.06 earnings per share for the current year.

Hedge Funds Weigh In On Cellectis

An institutional investor recently raised its position in Cellectis stock. Baillie Gifford & Co. grew its holdings in shares of Cellectis S.A. (NASDAQ:CLLSFree Report) by 1.3% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 827,248 shares of the biotechnology company’s stock after buying an additional 10,605 shares during the period. Baillie Gifford & Co. owned approximately 1.49% of Cellectis worth $2,192,000 as of its most recent filing with the SEC. 63.90% of the stock is currently owned by institutional investors and hedge funds.

Cellectis Company Profile

(Get Free Report)

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.

Featured Articles

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.